Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
11
×
life sciences
national blog main
clinical trials
fda
boston blog main
national top stories
boston top stories
eli lilly
europe top stories
indiana blog main
indiana top stories
new york top stories
san francisco blog main
san francisco top stories
europe blog main
new york blog main
boston
deals
detroit blog main
detroit top stories
genentech
novartis
raleigh-durham blog main
raleigh-durham top stories
roche
amgen
avapritinib
blueprint medicines
boulder/denver blog main
boulder/denver top stories
cancer
europe
investing
medullary thyroid cancer
national
non-small cell lung cancer
pralsetinib
san diego blog main
san diego top stories
What
drug
11
×
fda
11
×
approval
medicines
approved
cancer
friday
medicine
new
patients
therapeutics
therapy
won
blueprint
cholesterol
designed
eli
lilly
loss
marketing
oral
regulatory
ret
roche
second
treat
weight
wins
acquire
acute
address
addresses
affects
agency
agreed
aimmune
alkermes
allergy
americans
antipsychotic
Language
unset
11
×
Current search:
drug
×
biotech
×
unset
×
fda
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds